March 20th 2025, 1:00pm
In HER2-positive early breast cancer, Kadcyla shows sustained improvement in both invasive disease-free survival and overall survival versus Herceptin.
March 19th 2025, 8:00pm
Antibody-drug conjugates have had a tremendous impact on breast cancer care and treatment, according to Dr. Charles E. Geyer.
March 18th 2025, 7:00pm
Dr. Emre Yekedüz highlighted strategies that may improve patients' quality of life and mitigate treatment-related side effects in renal cell carcinoma.
March 18th 2025, 1:00pm
Dr. Debu Tripathy discusses recent research on the use of circulating tumor DNA in metastatic breast cancer care.
March 17th 2025, 4:00pm
Dr. Yufei Liu discusses how updates to precision radiation therapy are reshaping colorectal cancer care.
March 14th 2025, 7:00pm
Dr. Joseph Mikhael discusses the overlooked symptoms of multiple myeloma in honor of Myeloma Awareness Month.
March 14th 2025, 4:00pm
Dr. Deepa Jagadeesh discusses Ordspono's potential FDA approval for relapsed/refractory follicular lymphoma, highlighting its manageable toxicity and low CRS rate.
March 14th 2025, 12:00pm
Panelists discuss how the term "late-line" in relapsed/refractory multiple myeloma typically refers to patients who have progressed through multiple previous treatment regimens, indicating a more advanced disease state that has become resistant to several standard therapeutic approaches.
March 13th 2025, 7:00pm
Dr. Kevin Kalinsky discusses the role of targeted therapy and clinical decision-making in managing estrogen-driven, HER2-negative breast cancer.
March 13th 2025, 4:00pm
Dr. Alan Tan explores circulating tumor DNA, its role in clinical trials and its potential impact on patients with renal cell carcinoma.
FDA Approves Initiation of a New Trial in Recurrent Glioblastoma
The Benefit of Clinical Trial Enrollment for Patients With Cancer
Addressing Gaps, Challenges and Disparities in AYA Cancer Care
Unexpected Challenges 11 Years After Breast Cancer